Mural Oncology (NASDAQ:MURA) Trading 0.5% Higher – Here’s Why

Mural Oncology PLC (NASDAQ:MURA)’s stock price rose 0.5% on Wednesday . The stock traded as high as $2.10 and last traded at $2.10. Approximately 228,261 shares changed hands during trading, an increase of 96% from the average daily volume of 116,299 shares. The stock had previously closed at $2.09.

Analyst Upgrades and Downgrades

MURA has been the subject of several research analyst reports. Wall Street Zen downgraded Mural Oncology from a “hold” rating to a “strong sell” rating in a research report on Sunday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mural Oncology in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $12.00.

Mural Oncology Stock Up 0.5%

The company has a market cap of $36.39 million, a P/E ratio of -0.24 and a beta of 2.93. The business’s 50 day moving average is $2.05 and its 200 day moving average is $2.25.

Mural Oncology (NASDAQ:MURA) last released its quarterly earnings results on Monday, August 4th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.64). As a group, equities research analysts forecast that Mural Oncology PLC will post -7.54 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Armistice Capital LLC raised its stake in shares of Mural Oncology by 1.3% during the 1st quarter. Armistice Capital LLC now owns 1,722,000 shares of the company’s stock worth $2,170,000 after acquiring an additional 22,000 shares in the last quarter. Soleus Capital Management L.P. acquired a new position in shares of Mural Oncology during the second quarter worth $3,270,000. Orbimed Advisors LLC acquired a new position in shares of Mural Oncology during the second quarter worth $1,454,000. LMR Partners LLP acquired a new position in shares of Mural Oncology during the second quarter worth $1,276,000. Finally, Diametric Capital LP acquired a new position in Mural Oncology during the 2nd quarter valued at about $864,000. Institutional investors own 80.21% of the company’s stock.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.